Syntara
Syntara Limited is a clinical-stage drug development company focused on creating novel treatments for blood-related cancers and conditions linked to inflammation and fibrosis. Their expertise lies in amine oxidase inhibitors, targeting extracellular matrix dysfunction to develop medicines for diseases with high unmet needs. The company's lead candidate, amsulostat, is currently in Phase 2 trials for myelofibrosis.
Short position
Syntara (ASX:SNT) has 0.24% of its shares on issue reported as short positions as of 7 July 2026, or about 4,806,305 shares. Over the past 30 days that figure has risen 0.24 percentage points, and over 90 days it has risen 0.11 percentage points. SNT is classified in the Pharmaceuticals, Biotechnology & Life Sciences industry. All figures come from official ASIC short position reports, published with a four trading-day (T+4) delay.
Price & short interest
Toggle series, zoom, and compare · ASIC daily, T+4Syntara (SNT) short interest history
SNT Short Interest History
- 30-day change
- +0.24pp
- 90-day change
- +0.11pp
- 1-year change
- +0.23pp
- All-time high
- 0.24% (July 2026)
- All-time low
- 0.00% (May 2026)
Is SNT heavily shorted?
Not especially: 0.24% short interest is modest by ASX standards. ASIC requires positions of 0.01% of issued capital or $100,000 (whichever is less) to be reported.
How has SNT's short interest changed recently?
Over the past 30 days Syntara's short interest has been broadly stable, and over 90 days it has been broadly stable. The current level is 0.24% of shares on issue.
What is the highest SNT's short interest has been?
Since 2024, Syntara's short interest peaked at 0.24% in July 2026 and bottomed at 0.00% in May 2026.
Where does this data come from?
All figures are sourced from daily ASIC short position reports, published with a four trading-day (T+4) delay. Shorted aggregates the full history since 2024. See our methodology.